On September 30, 2021 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported it will present interim data on Rhenium-186 NanoLiposome (186RNL) from its ReSPECT Phase 1 clinical trial in recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting and Education Day being held November 18-21, 2021 in Boston, Massachusetts (Press release, Cytori Therapeutics, SEP 30, 2021, View Source [SID1234590576]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the abstract and poster session are as follows:
Title Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT Phase 1 Trial
Date November 19, 2021 at 7:30 – 9:30 p.m. ET
Location Exhibit Hall D, Hynes Convention Center
Presenter Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT clinical trial
Accepted abstracts will be made available on Thursday, November 11, 2021 at academic.oup.com/neuro-oncology/issue/22/Supplement_2.
A copy of the poster will be made available under the Presentations tab of the Investors section of the Company’s website at the time of the presentation at View Source